OneSkin Raises $20M for Groundbreaking Anti-Aging Peptide Technology
Biotech skincare pioneer, OneSkin, has triumphantly closed a Series A funding round, securing a robust $20 million to propel its innovative peptide-based anti-aging solutions. The round, which exceeded expectations, was spearheaded by Selva Ventures, and saw contributions from Unilever Ventures, Plus Capital, and a host of prominent investors such as Brazilian-American model Camila Alves McConaughey and tech entrepreneur Kevin Rose.
Established in 2016 by a team of four Brazilian PhD scientists, OneSkin has made a breakthrough with the development of the OS-01 peptide. This revolutionary ingredient is the first of its kind, scientifically validated to reverse the biological age of the skin by preventing the build-up of senescent, or “zombie”, cells that contribute to aging. The company’s pioneering work has not gone unnoticed, earning it a spot on Fast Company’s Most Innovative Companies of 2024 list and attracting a celebrity user base that includes Jennifer Aniston, Katy Perry, and Georgia May Jagger.
“This investment will enable us to intensify our dedication to delivering potent peptides that modulate aging at the cellular level,” stated Dr. Alessandra Zonari, Co-Founder and CSO. The funding will expedite the research and development of new formulas, while also broadening the brand’s consumer reach in the rapidly expanding longevity beauty market.
Source: https://longevity.technology/news/oneskin-secures-20m-series-a-to-advance-skin-health-solutions/